Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907852 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by TCR2 Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 11
- Study locations
NCT03907852 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is active but no longer recruiting, run by TCR2 Therapeutics. The registered enrollment target is 57 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT03907852, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by TCR2 Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 11
- Study locations
Study Summary
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG fludarabine
- DRUG cyclophosphamide
- BIOLOGICAL gavo-cel
Study Locations (11)
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- University of California, San Francisco - San Francisco
Florida
- University of Miami Sylvester Cancer Center - Miami
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- National Cancer Institute - Bethesda
North Carolina
- Duke University - Durham
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2028-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907852
The ClinicalTrials.gov registry entry for NCT03907852 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is TCR2 Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03907852 reports 11 study locations spanning 10 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03907852 about?
NCT03907852 is a clinical study titled "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer". Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell rec...
What is the current status of trial NCT03907852?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2019-04-15. Estimated completion is 2028-11-02.
What conditions does trial NCT03907852 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Mesothelioma, Non Small Cell Lung Cancer Metastatic.
What interventions are being tested in trial NCT03907852?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), fludarabine (DRUG), cyclophosphamide (DRUG), gavo-cel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03907852?
This trial is sponsored by TCR2 Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03907852 being conducted?
This trial has 11 study locations across California, Florida, Illinois, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.